DAT (chemotherapy)

DAT is a chemotherapy regimen for treatment of acute lymphoblastic leukemia (ALL). It is an acronym that stands for the drugs that are given as part of the treatment:

• Daunorubicin
• Cytarabine (also known as Ara-C)
• Thioguanine

Treatment regimen

The DAT regimen is typically given in cycles, with each cycle lasting a few weeks. The exact number of cycles and the duration of each cycle can vary depending on the patient's individual circumstances.

The drugs in the DAT regimen work by stopping the growth of cancer cells, which prevents the cancer from spreading. Daunorubicin and Cytarabine work by interfering with the DNA of cancer cells, preventing them from dividing and growing. Thioguanine works by blocking a specific enzyme that cancer cells need to grow.

Side effects

Like all chemotherapy treatments, the DAT regimen can cause side effects. These can vary from person to person, but may include:

• Nausea and vomiting
• Hair loss
• Fatigue
• Increased risk of infection
• Mouth sores
• Changes in appetite

It's important for patients to discuss any side effects they're experiencing with their healthcare team, as there are often ways to manage these side effects and improve the patient's quality of life during treatment.

See also

• Chemotherapy
• Acute lymphoblastic leukemia
• Daunorubicin
• Cytarabine
• Thioguanine